Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Míguez‐Rey, Dasom Choi, Seungmin Kim, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 1, pp. 41-58
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

COVID‐19 metabolism: Mechanisms and therapeutic targets
Tianshi Wang, Ying Cao, Haiyan Zhang, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 34
Mutational Pattern, Impacts and Potential Preventive Strategies of Omicron SARS-CoV-2 Variant Infection
Endeshaw Chekol Abebe, Markeshaw Tiruneh G Medhin, Awgichew Behaile T Mariam, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 1871-1887
Open Access | Times Cited: 30
Emerging trends and therapeutic applications of monoclonal antibodies
M. Janaki Ramaiah, Hari P. Nalluri, Prakash Narayana Reddy, et al.
Gene (2024) Vol. 925, pp. 148607-148607
Closed Access | Times Cited: 7
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
International Journal of Infectious Diseases (2022) Vol. 124, pp. 96-103
Open Access | Times Cited: 21
Development and validation of an LC–MS/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2
Yuanyuan Chai, Ling Zhou, Yan Yang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 260, pp. 116770-116770
Closed Access
Development of the TSR-based computational method to investigate spike and monoclonal antibody interactions
Tarikul I. Milon, Titli Sarkar, Yixin Chen, et al.
Frontiers in Chemistry (2025) Vol. 13
Open Access
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics
Vaishali Verma, N. D. Sinha, A. Raja
mAbs (2025) Vol. 17, Iss. 1
Open Access
T cells in SARS-CoV-2 infection and vaccination
Arthur P. Young
Therapeutic Advances in Vaccines and Immunotherapy (2022) Vol. 10
Open Access | Times Cited: 16
Therapeutic developments for SARS-CoV-2 infection—Molecular mechanisms of action of antivirals and strategies for mitigating resistance in emerging variants in clinical practice
Oana Săndulescu, Cătălin Apostolescu, Liliana Preoțescu, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 9
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, et al.
Cell Reports (2022) Vol. 41, Iss. 5, pp. 111528-111528
Open Access | Times Cited: 13
Synthesis of conjugates of (aR,7S)-colchicine with monoterpenoids and investigation of their biological activity
Ekaterina S. Shchegravina, Sofia D. Usova, Dmitry S. Baev, et al.
Russian Chemical Bulletin (2023) Vol. 72, Iss. 1, pp. 248-262
Open Access | Times Cited: 7
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
Jennifer E. Sager, Asma El‐Zailik, Julie Passarell, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 6, pp. 853-864
Open Access | Times Cited: 7
Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
Allison Claas, Meelim J. Lee, Pai‐Hsi Huang, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 757-769
Open Access | Times Cited: 2
Vectored immunoprophylaxis and treatment of SARS-CoV-2 infection in a preclinical model
Takuya Tada, Julia Minnee, Nathaniel R. Landau
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 23
Open Access | Times Cited: 6
Biologics in COVID-19 So Far: Systematic Review
Milton Arias, Henry Oliveros, Sharon Lechtig, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 783-783
Open Access | Times Cited: 8
Asia Pacific perspectives on the second year of the COVID‐19 pandemic: A follow‐up survey
Ruby Pawankar, Bernard Yu‐Hor Thong, Marysia Tiongco‐Recto, et al.
Clinical & Experimental Allergy (2022) Vol. 52, Iss. 8, pp. 965-973
Open Access | Times Cited: 8
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 4
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
Jaynier Moya, Marisol Temech, Sergio Parra, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 4
Adapting Neutralizing Antibodies to Viral Variants by Structure‐Guided Affinity Maturation Using Phage Display Technology
Frederik Peissert, Mattia Pedotti, Riccardo Corbellari, et al.
Global Challenges (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 4
Broad Epitope Coverage of Therapeutic Multi-Antibody Combinations Targeting SARS-CoV-2 Boosts In Vivo Protection and Neutralization Potency to Corner an Immune-Evading Virus
Ilse Roodink, Maartje van Erp, Andra Li, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 642-642
Open Access | Times Cited: 1
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 6
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
Yee Gyung Kwak, Je Eun Song, Jieun Kang, et al.
Infection and Chemotherapy (2022) Vol. 54, Iss. 4, pp. 781-781
Open Access | Times Cited: 5
Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience
Nicola Schiano Moriello, Antonio Riccardo Buonomo, Riccardo Scotto, et al.
Heliyon (2023) Vol. 9, Iss. 2, pp. e13126-e13126
Open Access | Times Cited: 2
Principles of Rational COVID-19 Therapy in Pediatrics
O. D. Nemyatykh, M. A. Maistrenko, Dina D. Demchenko, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 14, pp. 4731-4731
Open Access | Times Cited: 2
In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein
Woo-Ri Shin, Do Young ‍Kim, Sang Yong Kim, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1805-1816
Closed Access
Page 1 - Next Page

Scroll to top